Marked-up Version of Amendments

Additions to the text are indicated by underlining; deletions are indicated by square brackets.

In the Specification

On page 9, lines 29-34:

> Another embodiment of the present invention provides for a pharmaceutical composition which comprises a compound capable of inhibiting neurotoxicity, and a pharmaceutically acceptable carrier. The carrier may be a diluent, an aerosol, a topical carrier, an [aquous] aqueous solution, a nonaqueous solution or a solid carrier.

On page 15, lines 25-29:

> As used herein, the term "cytotoxicity" encompasses the negative metabolic, biochemical and physiological effects on a cell which may result in a debilitation of the [celluar] cellular functions, including but not limited to cell death.

On page 15, line 31, to page 16, line 4:

> In the practice of any of the methods of the invention or preparation of any of the pharmaceutical compositions [an], a "therapeutically effective amount" is an amount which is capable of inhibiting the binding of an amyloid-β peptide with a receptor for advanced glycation [eudproduct] endproduct. Accordingly, the effective amount will vary with the subject being treated, as well as the condition to be treated. For

the purposes of this invention, the methods of administration are to include, but are not limited to, administration cutaneously, subcutaneously, intravenously, parenterally, orally, topically, or by aerosol.